Recombinant Human Anti-HBV preS1 Antibody (2H5-A14) (CAT#: PABC-406)

Figure 1 The broad and potent neutralization activity of 2H5-A14 against HBV infection.

2H5-A14 neutralized HBV aenotypes B, C, and D (A). In comparison to the prototype preS1 lipopeptides of Myrcludex-B. KR127 and HBIG in neutralizing HBV infection of HepG2-hNTCP cells, 2H5-A14 showed superior activity (B).

Li, D., He, W., Liu, X., Zheng, S., Qi, Y., Li, H., ... & Du, K. (2017). A potent human neutralizing antibody Fc-dependently reduces established HBV infections. elife, 6, e26738.

Figure 2 IHC staining of HBsAg and HBcAg in liver tissues from sacrificed mice at the end of the experiment.

Intrahepatic HBsAg and HBcAg levels were detected by specific antibodies conjugated with Alkaline phosphatase (AP) and horseradish peroxidase (HRP), respectively. Each set of images represents the results for one mouse of each group.

Li, D., He, W., Liu, X., Zheng, S., Qi, Y., Li, H., ... & Du, K. (2017). A potent human neutralizing antibody Fc-dependently reduces established HBV infections. elife, 6, e26738.

Figure 3 IHC staining of human cytokeratin-18 (hCK18) and HBsAg in serial sections of liver tissues from sacrificed hFRG mice at the end of the experiment (dpi 89).

Intrahepatic HBsAg was detected by a specific anti-HBsAg mouse mAb, followed by HRP-anti-mouse secondary Ab and stained brown using DAB substrate, nuclei were stained blue by Hematoxylin. Human hepatocytes in consecutive tissue sections were visualized by staining with a human-specific hCK18 mAb and DAB substrate in blue violet, nuclei were stained with Nuclear Fast Red.

Li, D., He, W., Liu, X., Zheng, S., Qi, Y., Li, H., ... & Du, K. (2017). A potent human neutralizing antibody Fc-dependently reduces established HBV infections. elife, 6, e26738.

Figure 4 2H5-A14 mediated ADCC and ADCP.

The target cells used were suspension 293F cells expressing the 2H5-A14 epitope or the mutant epitope. The effector cells were human blood monocyte-derived macrophages. The E: T ratio was about 1:1. For the ADCC activity (left), ADCC-inactive Fc variant (2H5-A14-DANA) of 2H5-A14 or isotype-matched control Abs were tested at the indicated concentrations with three replicates. For the ADCP assay (right), the target cells were labeled with CFSE fluorescent dye prior to mixing with macrophages. ADCP activity was monitored by fluorescence microscopy. The phagocytosis index was determined as the number of CFSE-positive target cells per 100 macrophages.

Li, D., He, W., Liu, X., Zheng, S., Qi, Y., Li, H., ... & Du, K. (2017). A potent human neutralizing antibody Fc-dependently reduces established HBV infections. elife, 6, e26738.

Figure 5 Therapeutic efficacy of 2H5-A14 in mouse models.

2H5-A14 protected NTCP-edited mice from HDV infection. A total of 21 mice were IP administered 2H5-A14, HBIG, or matched isotype control Ab at the indicated concentrations at 9 days after birth. One hour later, each mouse was challenged with 1x 10¹⁰ GE of HDV and was then sacrificed on post infection day 6. The liver tissues were collected from each mouse. HDV total RNA levels and the edited NTCP gene expression were measured by qPCR.

Li, D., He, W., Liu, X., Zheng, S., Qi, Y., Li, H., ... & Du, K. (2017). A potent human neutralizing antibody Fc-dependently reduces established HBV infections. elife, 6, e26738.

Figure 1 Recombinant Human Anti-HBV preS1 Antibody (PABC-406) in SDS-PAGE

Lane 1: Non-reduced mAb
Lane 2: Reduced mAb